Research Article
High Prevalence but Insufficient Treatment of Iron-Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results of a Population-Based Cohort
Table 3
Details on the 8 patients with persisting iron-deficiency anemia despite of treatment.
| Type of IBD | Hb level (g/dL) | Way of iron administration | Duration of substitution (months) | Disease-specific treatment | Activity of IBD |
| Crohn’s disease | 11.1 | oral | >12 | — | Remission | Crohn’s disease | 10.7 | Oral and i.v. | 1–3 | Prednisolone | Chronic active | Crohn’s disease | 13.3 (transferrin saturation 9%) | oral | 1–3 | — | Remission | Crohn’s disease | 7.4 | oral | 1–3 | Methotrexate | Chronic active | Ulcerative colitis | 8.4 | oral | >12 | Mesalamine, prednisolone | Chronic active | Crohn’s disease | 9.7 | i.v. | 1–3 | Methotrexate | Chronic active | Ulcerative colitis | 9.4 | oral | <1 | Mesalamine, prednisolone | Remission | Ulcerative colitis | 11.9 | oral | 1–3 | Mesalamine | Remission |
|
|